Stentys Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell Technologies To Distribute Its Novel Drug-Eluting Stent

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News : STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced it has entered into a five year agreement with Micell Technologies Inc. to be the exclusive distributor of the MiStent coronary stent worldwide (excluding the United States, Canada, China, South Korea and Japan).

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, explains: “We are thrilled to launch this exciting new product that is designed to outperform the market-leading workhorse stents thanks to a unique coating technology. Our customers will now have the opportunity to use MiStent for routine procedures and STENTYS Self-Apposing stent for complex vessel anatomy that requires optimal apposition, both of which are designed for safe vessel healing and improved patient outcomes.“

Help employers find you! Check out all the jobs and post your resume.

Back to news